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Summary
Alteration in the differentiated state of smooth muscle
cells (SMCs) is known to be integral to vascular devel-
opment and the pathogenesis of vascular disease.
However, it is still largely unknownhow environmental
cues translate into transcriptional control of SMC
genes. We found that dEF1 is upregulated during
SMC differentiation and selectively transactivates the
promoters of SMC differentiation marker genes, SM
a-actin and SM myosin heavy chain (SM-MHC). dEF1
physically interacts with SRF and Smad3, resulting in
a synergistic activation of SM a-actin promoter. Chro-
matin immunoprecipitation assays and knockdown
experiments showed that dEF1 is involved in the con-
trol of the SMC differentiation programs induced by
TGF-b signaling. Overexpression of dEF1 inhibited
neointima formation and promoted SMC differenti-
ation, whereas heterozygous dEF1 knockout mice
exhibited exaggerated neointima formation. It thus
appears dEF1 mediates SMC differentiation via inter-
action with SRF and Smad3 during development and
in vascular disease.
Introduction
Unlike striated muscle cells, smooth muscle cells
(SMCs) are not terminally differentiated, even in adult
blood vessels, and the plasticity they retain enables
them to modify their phenotype in response to environ-
mental cues (Owens et al., 2004). It is well documented
that phenotypically modulated SMCs are centrally in-
volved in the pathogenesis of vascular disease. Conse-
quently, elucidation of the mechanisms that control the
differentiated state of SMCs is critically important for
understanding not only vascular development but also
the pathology of vascular disease.
*Correspondence: manabe-tky@umin.ac.jpA number of transcription factors have been impli-
cated in SMC differentiation, but unlike in skeletal mus-
cle, no single transcription factor identified so far can, by
itself, induce SMC differentiation. Recent studies have
clearly demonstrated that SMC gene expression is
highly context dependent and is controlled not by
a single SMC-specific transcription factor but by the
interactions between multiple factors and cofactors,
which likely form networks that selectively and coordi-
nately control gene expression in response to environ-
mental cues (Owens et al., 2004; Manabe and Nagai,
2003). Transcription factors and cofactors reportedly
involved in such networks include SRF, GATA6, and
myocardin (Miano, 2003; Owens et al., 2004); though it
is still largely unknown how these factors interact within
the networks to execute SMC-specific gene programs.
SMC-specific transcriptional regulatory modules very
often contain the CArG element, a target element of se-
rum response factor (SRF); indeed, in vivo expression of
virtually all of the SMC-specific genes studied so far de-
pends on CArG elements (Miano, 2003). However, SRF
is ubiquitously expressed in a variety of cell-types and
is necessary for expression of a large number of non-
muscle genes. Thus, one critical question in the field
has been: How do ubiquitously expressed factors such
as SRF regulate SMC-specific transcription? One clue
may come from the recent report that a transcription
cofactor, myocardin, is necessary for SMC-specific
SRF-dependent transcription (Wang et al., 2003). Still,
it remains unclear how environmental cues translate
into alterations in gene transcription that depend on
SRF and myocardin.
One external factor thought to be important for control
of SMC differentiation is TGF-b, which is able to induce
neural crest stem cells to express SMC differentiation
marker genes, such as SM a-actin, and to augment
expression of SMC markers in cultured SMCs (Shah
et al., 1996). In addition to these in vitro studies, gene
knockout studies in which TGF-b was targeted con-
firmed that TGF-b signaling is essential for proper vessel
formation (Dickson et al., 1995), while targeting endo-
glin,ALK-1,ALK-5 (TGF-b receptors), orSmad5 resulted
in reduced SMC/pericyte recruitment and proliferation
within vessels (Li et al., 1999; Oshima et al., 1996; Yang
et al., 1999). TGF-b has also been shown to be crucially
involved in SMC differentiation and proliferation in vas-
cular injury models (Mallat et al., 2001). And given the
importance of SRF in SMC-specific transcriptional pro-
grams, it seems likely that it, too, is involved in TGF-b-
dependent transcriptional control. Indeed, one earlier
report showed that two CArG boxes in the SM a-actin
promoter were necessary for TGF-b responsiveness
(Hautmann et al., 1997). The molecular basis for the ef-
fects of TGF-b on SRF-dependent SMC gene expression
is not yet clear, however.
dEF1 (also called ZEB-1) is a transcription factor that
contains two clusters of zinc fingers and a homeodomain
and was first identified as a factor binding to an
enhancer in the chicken d1-crystallin gene (Funahashi
et al., 1993; Postigo and Dean, 1997). In mouse embryo,
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94Figure 1. dEF1 Expression in Tissues and
during SMC Differentiation
(A) Northern blot analysis of tissue distribu-
tion of dEF1 mRNA in adult rats.
(B) dEF1 expression in the cardiovascular
system. dEF1 knockout mice harbor a LacZ
reporter gene controlled by the dEF1 regula-
tory program (Takagi et al., 1998). Tissues
taken from adult dEF1+/2 mice were sub-
jected to X-gal staining and counterstained
with nuclear fast red. Cross-sections of the
thoracic aorta (Ba) and femoral artery (Bb)
are shown. Scale bars, 50 mm.
(C) dEF1 expression during SMC differentia-
tion of A404 cells. Expression of dEF1, SM
a-actin, and SM-MHC was analyzed by semi-
quantitative multiplex PCR with primer sets
for the gene of interest and an internal control
(18S rRNA).
(D) Real-time PCR analysis of dEF1 expres-
sion in the aortas of embryos (E18.5) and
adult mice. The relative numbers of dEF1
transcripts were normalized to those of 18S.
Bars indicate relative copy number and SE.dEF1 expression was first detected in the headfold and
the presomitic and lateral plate mesoderm on embry-
onic day (E) 8.5 and in the derivatives of the cranial neu-
ral crest and limb buds on E9.5 (Takagi et al., 1998).
Given that vascular SMCs are derived from a variety of
embryonic progenitors, including lateral mesoderm,
cranial mesenchyme, and the neural crest (Majesky,
2003), the expression pattern of dEF1 is suggestive of
a role in SMC biology, though the function of dEF1 in
the cardiovascular system has not yet been explored.
Interestingly, recent studies have shown that dEF1 inter-
acts with Smad proteins, the basic components of intra-
cellular TGF-b signaling pathways.
In the present study, we identified dEF1 as a candidate
gene that might control SMC differentiation, and subse-
quent analyses showed that dEF1 is selectively ex-
pressed in vascular SMCs and that it controls SMC-spe-
cific gene expression by mediating TGF-b signaling and
SRF-dependent transcription. Overexpression of dEF1
inhibited neointima formation and promoted SMC differ-
entiation, whereas heterozygous dEF1 knockout mice
exhibited exaggerated neointima formation. Taken to-
gether, these findings suggest that dEF1 plays an impor-
tant role in the control of SMC differentiation occurring in
response to environmental cues during development and
in vascular diseases.
Results
dEF1 Is Preferentially Expressed in Vascular SMCs
and Is Developmentally Regulated
With the aim of identifying transcription factors involved
in SMC differentiation, we searched databases for tran-
scription factors containing C2H2-type zinc fingers anddiscovered several that might be expressed in SMCs.
Among these was dEF1, which in adult rats is expressed
in the aorta, heart, carotid artery, brain, and skeletal mus-
cle but not in visceral smooth muscle tissues, such as
the bladder, stomach, and small intestine (Figure 1A).
Because this finding suggested that dEF1 might be ex-
pressed in vascular SMCs, we next carried out a more
detailed analysis of the localization of dEF1 in cardiovas-
cular tissues. Tissues obtained from dEF1knockout mice
harboring a LacZ reporter gene whose expression mim-
icked endogenous dEF1 expression (Takagi et al., 1998)
were stained with X-gal. As expected, positive staining
was observed in SMCs located in the media of arteries
(Figure 1B) as well as in cardiomyocytes (data not
shown). Positively stained cells were also occasionally
observed in veins (data not shown). Arterial endothelial
cells were not positively stained (Figure 1B).
To analyze dEF1 expression during SMC differentia-
tion, we utilized the A404 cell line, which is an embryonic
carcinoma P19-derived in vitro SMC differentiation
system (Manabe and Owens, 2001b). Undifferentiated
A404 cells do not express SMC differentiation marker
genes (Figure 1C), but when stimulated with retinoic
acid, they rapidly acquire SMC phenotypes and express
such SMC markers as SM myosin heavy chain (SM-
MHC). Likewise, expression of dEF1 was upregulated
during SMC differentiation in this system (Figure 1C).
In the aorta, moreover, greater expression of dEF1 was
seen in adult mice than in E18.5 embryos (Figure 1D).
Taken together, these findings suggest that dEF1
expression is restricted to SMCs in the arterial wall,
that its expression is regulated by the differentiation
state of those cells, and that, perhaps, dEF1 controls
the differentiation state of SMCs.
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95Figure 2. dEF1 Transactivated SMC Differen-
tiation Marker Gene Promoters
(A) Effects of dEF1 on the regulatory region of
SMC differentiation marker genes. Reporter
genes driven by the regulatory region of indi-
cated genes were transiently cotransfected
with the dEF1 expression vector or an empty
vector. The b-galactosidase activity of each
reporter construct cotransfected with dEF1
expression vector was normalized to that
cotransfected with the empty vector. Bars in-
dicate relative b-galactosidase activity and SE.
(B–E) Effect of dEF1 on expression of endoge-
nous SMC differentiation marker genes. Cul-
tured SMCs were infected with either the
dEF1 adenovirus or empty adenovirus at 20
MOI and then harvested 36 hr after infection.
mRNA expression was analyzed by real-time
RT-PCR. dEF1 detected in (B) included tran-
scripts from both endogenous and exogenous
genes. The copy number of each transcript
was normalized to that of 18S, after which
the expression was further normalized to that
of cells infected with empty adenoviral vector.
Bars indicate relative copy number and SE.
(F–I) Effects of dEF1 knockdown on SMC
differentiation of A404 cells. A404 cells were
transfected with either dEF1-siRNA or scram-
bled-siRNA. Twenty-four hours after transfec-
tion, the cells were treated with all-trans reti-
noic acid. Two and 4 days after the initiation
of differentiation, the cells were harvested
and subjected to Western analysis of dEF1
(F) and real-time PCR analysis of dEF1 (G),
SM a-actin (H), and SM-MHC (I). Bars indicate
relative copy number and SE.dEF1 Controls SMC Differentiation
Marker Gene Expression
To test the hypothesis that dEF1 controls the differenti-
ated state of SMCs, we used transient transfection anal-
ysis to examine its contribution to the transcriptional reg-
ulation of SMC differentiation marker gene expression
(Figure 2A). We found that dEF1 transactivated the tran-
scriptional regulatory regions of SM-MHC (24.2 to +11.6
kb) and SM a-actin (22.6 to +2.7 kb), as well as the
SM22a promoter (2441 to +41 bp), all of which have
been shown to drive SMC-specific gene expression
in vivo (Owens et al., 2004). By contrast, dEF1 did not ac-
tivate the regulatory region (25 to +7 kb) of SMemb,
a marker gene expressed in embryonic and phenotyp-
ically modulated SMCs. Consistent with these effects
on the promoter reporters, overexpression of dEF1 in
cultured rat aortic SMCs with an adenoviral expression
vector led to significant increases in the endogenous
expression of SM a-actin (2.1-fold increase) and SM-MHC
(2.3-fold), as compared to those seen in SMCs infected
with empty adenovirus (Figures 2C and 2D). The expres-
sion level of SMemb was somewhat reduced in the
dEF1-overexpressing cells (Figure 2E).
To further test the involvement of dEF1 in SMC differ-
entiation, dEF1 expression was knocked down in A404cells with siRNA, after which the cells were induced to
differentiate. Due to the low transfection efficiency of
A404 cells and the long durations of culture after the
siRNA transfection, the levels of knockdown of dEF1 ex-
pression were modest (Figures 2F and 2G). Neverthe-
less, expression of SM a-actin and SM-MHC mRNA
was significantly inhibited (Figures 2H and 2I), suggest-
ing that knockdown of dEF1 delayed differentiation of
A404 cells.
dEF1 Controls the SM a-actin Proximal Promoter
To define how dEF1 controls SMC differentiation marker
gene transcription, a set of reporter plasmids encoding
various SM a-actin and SM-MHC deletion constructs
were cotransfected with the dEF1 expression plasmid.
The results obtained with the SM-MHC reporter indi-
cated that dEF1 affects the transcriptional activity of
the SM-MHC regulatory region (24.2 to +11.6 kb) by act-
ing via multiple subregions within it (data not shown). On
the other hand, the initial deletion analysis of the SM
a-actin transcriptional regulatory region (22.6 to +2.7
kb) suggested that dEF1 mainly controlled transcription
of this gene via its proximal promoter (Figure 3B). To
facilitate our analysis of dEF1 activity, therefore, we
focused on the SM a-actin proximal promoter. Deletion
Developmental Cell
96Figure 3. Analysis of dEF1-Mediated Transactivation of SM a-actin Promoter
(A) Schematic representation of the transcriptional regulatory regions of SM a-actin.
(B) Effects of dEF1 on the transcriptional activity of SM a-actin deletion mutants. Luciferase reporter constructs containing the indicated SM
a-actin deletion mutants were transiently cotransfected into cultured SMCs along with either dEF1 expression vector or empty vector. Bars
indicate relative luciferase activity and SE; *p < 0.05.
(C) Effects of mutations within the cis-regulatory elements on transactivation of the SM a-actin promoter (2271/+42) by dEF1. THR, CArGs, TCE,
and E boxes were mutated within the2271/+42 bp construct. The luciferase activity of each reporter construct cotransfected with the dEF1 vec-
tor was normalized to the activity of the reporter cotransfected with empty vector. Effects of the mutations on the basal SM a-actin promoter
activity are shown in Figure S5. Bars indicate relative luciferase activity and SE.
(D) EMSA analysis of the binding of dEF1 to the SM a-actin promoter. 32P-labeled wild-type THR (wt), mutant THR (mut), E1, and E2 oligonucle-
otides were incubated with SMC nuclear extracts and subjected to EMSA. In lanes 2–7, a molar excess of the indicated cold competitor was
added to the reactants; in lanes 8 and 9, anti-dEF1 or anti-USF antibody was added. Asterisks indicate nonspecific shift bands.
(E) Binding of SMC transcription factors to CArG-B. Nuclear extracts of cultured SMCs were incubated with biotinylated wild-type or mutant
CArG-B probe, and the probe and bound proteins were collected with streptavidin-conjugated magnet beads. The bound proteins were sub-
jected to SDS-PAGE and immunoblotting with anti-SRF, anti-dEF1, and anti-Smad3 antibodies.
(F) Binding of in vitro translated proteins to the CArG-B probe. SRF and/or dEF1 were incubated with the biotinylated wild-type CArG-B probe.
Input proteins (1 and 2) and bound proteins (3 and 4) were immunoblotted with anti-SRF (1 and 3) or anti-dEF1 antibody (2 and 4).
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97of the 50-flanking region from22.6 kb to2271 bp had no
effect on the level of transactivation by dEF1 (6.3- to 7.4-
fold over the activity seen with empty vector), while de-
letion of the first intronic region between +43 bp and
+2.7 kb augmented transactivation by dEF1 (11.4-fold
with 2271 to +42 bp versus 7.1-fold with 2271 bp
to +2.7 kb). Further deletion of the 2271/281 bp region
resulted in significant reductions in dEF1-mediated re-
porter activity, which suggests that dEF1 affected pro-
moter activity mainly via the proximal promoter region
between 2271 and +45 bp.
Within the 271-bp 50-flanking region, there are two E
boxes, a potential cis-element called THR (TGF-b1 hy-
persensitivity region [Cogan et al., 2002]), two CArG ele-
ments, and a TCE (TGF-b control element [Hautmann
et al., 1997]), which are well conserved among species
(Shimizu et al., 1995). Although dEF1 reportedly binds
to a subset of E box sequences (Sekido et al., 1994),
the SM a-actin E boxes do not accommodate very well
the consensus binding sequence for dEF1 (CACCTG).
To investigate the involvement of the E boxes, THR,
CArG, and TCE in transactivation by dEF1, they were
mutated within the 2271/+42 bp reporter construct.
Mutation of the E boxes, CArG-A, or TCE had little effect
on transactivation of the promoter by dEF1 (Figure 3C).
By contrast, mutation of THR or CArG-B significantly
impaired promoter activation, and double mutation of
THR and CArG-B further decreased the reporter activity
transactivated by dEF1. THR and CArG-B thus appear
to be required for transactivation of the SM a-actin
2271/+42 bp region by dEF1.
We next analyzed the binding of dEF1 to the THR and
CArG-B in vitro. In EMSAs using nuclear extract pre-
pared from cultured SMCs, the THR probe elicited a spe-
cific band shift (Figure 3D, lane 1). This shift was partially
inhibited by a cold probe for the E box (CACCTG) within
the immunoglobulin k enhancer (lanes 2 and 3), but it
was much more efficiently inhibited by cold probe for
the THR element (lanes 4 and 5). On the other hand,
cold probe in which the THR element was mutated did
not inhibit the band shift (lanes 6 and 7). Moreover, the
band was super shifted by the addition of anti-dEF1
antibody (lane 8), confirming that the band contained
dEF1. Anti-USF1 antibody did not affect the shift band.
Probes containing the SM a-actin E boxes did not shift
bands containing dEF1 (lanes 11 and 12), indicating
that dEF1 binds to the THR element but not the E boxes
within the SM a-actin proximal promoter region. It thus
appears that dEF1 transactivates the SM a-actin pro-
moter at least in part via binding to the THR element.
dEF1 Interacts with SRF
The results of the reporter analyses indicate that CArG-B
is also required for dEF1 action. However, the CArG-B
probe did not form shift bands with in vitro translated
dEF1 in EMSA (data not shown), suggesting dEF1 might
be involved in the activity of CArG-B via interactions with
SRF. To address this possibility, we analyzed binding
proteins to CArG-B by DNA affinity binding assays
(Suzuki et al., 1993). When the biotinylated CArG-B
probe was incubated with SMC nuclear extracts, SRF,
dEF1, and Smad3 were detected in the bound proteins
(Figure 3E). To test whether dEF1 requires SRF to bind
CArG-B, the biotinylated CArG-B probe was incubatedwith in vitro translated dEF1 protein in the presence or
absence of SRF. As shown in Figure 3F, dEF1 bound
the CArG-B probe only when SRF was present.
To further characterize interactions between dEF1 and
SRF, we carried out coimmunoprecipitation experi-
ments with whole-cell lysates prepared from cultured
SMCs (Figures 4A and 4B). When the lysates were sub-
jected to immunoprecipitation, we detected SRF in im-
munoprecipitates pulled down with anti-dEF1 antibody
(Figure 4A) and detected dEF1 in those pulled down
with anti-SRF antibody (Figure 4B), which indicates
that endogenous dEF1 protein physically interacts with
SRF protein.
We then determined which domains of dEF1 and SRF
interact with one another with expression vectors en-
coding truncated forms of dEF1 and SRF. Coimmuno-
precipitation experiments showed that the two proteins
interact mainly via dEF1 regions containing two zinc-fin-
ger domains and a SRF region containing a MADS box
(Figures 4C and 4D).
dEF1 Cooperates with SRF and Smad3 to Activate
the SM a-actin Promoter
Previous studies have shown that in AKR-2B fibroblasts,
the reactivity of THR can vary in in vivo footprinting
evoked by TGF-b (Becker et al., 2000). Moreover, Pos-
tigo recently reported that in osteoblasts dEF1 interacts
with Smads, thereby playing a key role in the regulation
of transcription mediated by TGF-b signaling (Postigo,
2003). These findings suggested that dEF1 might inter-
act with Smads and play a role in TGF-b signaling in
SMCs. To test that hypothesis, we first cotransfected
a luciferase reporter vector containing the SM a-actin
regulatory region (22.6 to +2.7 kb) with vectors encod-
ing dEF1 and Smad3 into SMCs. Subsequent reporter
analyses showed synergistic activation of SM a-actin
reporter activity by dEF1 and Smad3 (Figure S1A).
Conversely, Smad7, an inhibitory Smad, suppressed
transactivation of the SM a-actin by dEF1, lending addi-
tional support to the idea that Smads are involved in
transcriptional control by dEF1 (Figure S1B). That dEF1
physically interacts with Smads was confirmed by coim-
munoprecipitation experiments with whole-cell lysates
of SMCs. dEF1 was detected in immunoprecipitates
pulled down with anti-Smad3 antibody (Figure 5A), and
Smad3 was detected in immunoprecipitates pulled down
with anti-dEF1 antibody (Figure 5B).
Our coimmunoprecipitation (Figure 4), DNA affinity
binding, and reporter (Figure 3) analyses showed that
dEF1 interacts with SRF in SMCs. Interestingly, SRF
also interacts with Smads (Qiu et al., 2003), while CArG
elements are required for TGF-b-dependent activation
of SM a-actin (Hautmann et al., 1997), which suggests
that SRF is involved in TGF-b-dependent transcriptional
control. Bearing that in mind, we next tested whether
dEF1, SRF, and Smad3 might all interact in the transcrip-
tional control of SM a-actin expression. Our reporter
analyses consistently showed that overexpressing
SRF in rat aortic SMCs inhibited somewhat the activity
of SMC differentiation marker gene promoters, including
those of SM a-actin and SM-MHC, whereas SRF trans-
activated those promoters in non-SMC cells, such
as NIH3T3, BALB/3T3, and COS cells. Although the
exact mechanism for this SMC-selective inhibition is
Developmental Cell
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(A and B) Physical association of dEF1 and
SRF. Whole-cell lysates prepared from cul-
tured rat aortic SMCs were incubated with
anti-dEF1 antibody (A), anti-SRF antibody
(B), or normal IgG (control). The reactants
were immunoprecipitated with protein G (A)
or anti-rabbit IgG (B) agarose-conjugated
antibody, and immunoprecipitates were sub-
jected to immunoblotting with anti-SRF anti-
body (A) or anti-dEF1 antibody (B).
(C and D) Analysis of the interaction between
domains within dEF1 and SRF proteins. Myc-
tagged dEF1 or SRF deletion constructs were
transfected into cultured SMCs. Lysates of
the cells were incubated with the indicated
antibodies (IP), and immunoprecipitates
were subjected to immunoblot with the indi-
cated antibodies (IB).
(E) The domains are schematically illustrated.unknown, competition for coactivators has been pro-
posed as a possible mechanism (Prywes and Zhu,
1992). Because of this inhibitory effect of SRF, we
used NIH3T3 cell in the following experiments. In those
cells, SRF transactivated the full-length (22.6 to +2.7
kb) SM a-actin reporter, eliciting a 13.8-fold increase in
activity (Figure 5C). By themselves, Smad3 or dEF1
each only slightly increased the luciferase activity of
the full-length (22.6 to +2.7 kb) SM a-actin reporter
(3.2-fold and 2.2-fold, respectively) (Figure 5C). Interest-
ingly, introduction of a constitutively active form of the
TGF-b type 1 receptor, caALK5, increased basal re-
porter activity (8.2-fold increase versus control without
caALK5) (Figure 5C versus Figure 5D), and under those
conditions, Smad3 and dEF1 clearly augmented trans-
activation of the reporter (6.4- and 5.6-fold increase
over the control with caALK5), suggesting that the activ-
ities of both the SM a-actin promoter and dEF1 are de-
pendent upon Smad signaling. Cotransfection of SRF
and either Smad3 or dEF1 resulted in synergistic activa-
tion of the reporter activity, irrespective of the inclusion
of caALK5 (Figures 5C and 5D). Moreover, cotransfec-
tion of constructs for SRF, Smad3, and dEF1 resulted
in further activation of the reporter. We found similar pat-
terns of activation of the 2271/+42 bp construct (Fig-
ure S2), although overexpression of SRF increased the
reporter activity to a much greater extent. Thus, SRF,dEF1, and Smad all appear to be important for SM a-ac-
tin transcription, and the synergistic activation observed
with combinations of these transcription factors sug-
gests that they interact to control promoter activity.
dEF1 Is Involved in TGF-b-Dependent
Transcriptional Control of SM a-actin
The involvement of dEF1 in Smad3-dependent tran-
scriptional control in SMCs suggests that dEF1 may be
required for TGF-b-induced SM a-actin transcription.
To test this idea, we first examined TGF-b-evoked
dEF1 expression. Levels of dEF1 protein were increased
by TGF-b stimulation, peaking within 12 hr and then re-
turning to baseline within 24 hr (Figure 5E). Levels of
dEF1 mRNA were also increased by TGF-b (Figure 5G).
We then analyzed the effect of dEF1 knockdown with
siRNA (Figures 5F and 5G). dEF1-siRNA or a control-
scrambled siRNA was transfected into cultured SMCs,
after which the cells were stimulated with TGF-b.
dEF1-siRNA successfully knocked down expression of
dEF1 at both the mRNA (Figure 5F) and protein (Fig-
ure 5G) levels. In cells transfected with control siRNA,
TGF-b induced dEF1 expression that peaked within
4 hr after stimulation (Figure 5G). In those cells, SM a-ac-
tin expression was clearly increased within 4 hr and
peaked within 8 hr after TGF-b stimulation. In cells trans-
fected with dEF1-siRNA, by contrast, the TGF-b-induced
dEF1 Promotes Vascular SMC Differentiation
99Figure 5. dEF1 in TGF-b Signaling
(A and B) Physical association between Smad
and dEF1. SMC lysates were incubated with
the indicated antibodies (IP) and immunopre-
cipitated. dEF1 (A) or Smad3 (B) in the immu-
noprecipitate was detected with the corre-
sponding antibodies.
(C and D) Effects of SRF, Smad3, and dEF1 on
the SM a-actin promoter. NIH3T3 cells were
cotransfected with full-length SM a-actin
luciferase plasmid and expression vectors en-
coding SRF, Smad3, and/or dEF1, with or
without constitutively active ALK5 (caALK5),
as indicated. The luciferase activity was
normalized to that of the SM a-actin reporter
cotransfected with empty plasmid. Bars indi-
cate relative luciferase activity and SE.
(E) InductionofdEF1protein by TGF-bstimula-
tion. Rat aortic SMCs were cultured in serum-
free defined medium for 4 days, after which
TGF-b (2.5 ng/ml) was added to the medium.
Whole-cell lysates were subjected to Western
analyses of dEF1 and b-tubulin.
(F) Cells transfected with either dEF1-siRNA or
control siRNA and incubated in serum-free
medium for 24 hr were harvested, after which
their whole-cell lysates were subjected to
Western analyses.
(G) Effects of dEF1 knockdown on SM a-actin
expression. Either dEF1-specific siRNA or
control scrambled siRNA was transfected
into SMCs. Twenty-four hours later, the
medium was changed to serum-free defined
medium for an additional 24 hr, after which
TGF-b (2.5 ng/ml) was added for the indicated
times. mRNA expression was analyzed by
real-time PCR. Solid lines represent gene
expression in cells transfected with the
scrambled siRNA; dotted lines, expression in
cells transfected with dEF1-siRNA. Error bars
represent SE from triplicate culture wells;
*p < 0.05 (two-way ANOVA).
(H–J) ChIP analysis of dEF1, SRF, and Smad3
binding to the endogenous SM a-actin pro-
moter region containing the THR under TGF-
b1 stimulation. SMCs were cultured in defined
serum-free medium for 4 days and then
treated with TGF-b1 (2.5 ng/ml) for 12 hr. Chromatin samples prepared from these cells were subjected to ChIP analysis. PCR was carried out
to detect the SM a-actin promoter. Lanes 1 and 2 show amplification of total input DNA. Lanes 3 and 4 show PCR amplification of control samples
precipitated with no antibody. Lanes 5 and 6 show amplification of target sequences within the immunoprecipitates. The sequence of GAPDH,
which does not contain a dEF1 binding sequence, was also amplified to confirm the specificity of the assay (H).upregulation of dEF1 was clearly suppressed (Fig-
ure 5G), as were the level of SM a-actin expression at
0 hr and its subsequent upregulation. Thus, knocking
down dEF1 in SMCs attenuated the upregulation of SM
a-actin otherwise seen following TGF-b stimulation, in-
dicating dEF1 plays an important role in the TGF-b-de-
pendent transcriptional control of SM a-actin expres-
sion. In addition, we also found that knocking down
Smad3 resulted in inhibition of SM a-actin expression
(Figure S3).
To confirm that endogenous dEF1, SRF, and Smad
bind to the endogenous SM a-actin promoter in intact
chromatin, cross-linked chromatin samples prepared
from SMCs were subjected to chromatin immunoprecip-
itation (ChIP) assays. The SM a-actin promoter region
was pulled down with antibodies against dEF1 or
Smad3 in SMCs treated with TGF-b1 (Figures 5H and
5I) but was almost undetectable in the precipitants ofuntreated cells. The binding of SRF to the promoter
was also augmented by TGF-b stimulation (Figure 5J).
Clearly, TGF-b stimulation induces binding of dEF1,
Smad3, and SRF to the endogenous SM a-actin
promoter.
dEF1 Plays a Role in SMC Differentiation In Vivo
We then examined the in vivo expression of SMC differ-
entiation marker genes in the aortas of dEF1 knockout
mice (Figure 6). We observed no apparent gross abnor-
malities in the cardiovascular systems of either dEF12/2
or dEF1+/2mice. Given the lethality of the dEF12/2 geno-
type, we decided to examine expression of SMC differ-
entiation marker genes in aortas collected from embryos
on E18.5. Using real-time PCR, we found that the levels
of expression of SM a-actin, SM22a, and SM-MHC were
lower in both dEF12/2 and dEF1+/2 embryos than in wild-
type embryos (Figures 6C–6F), while expression of
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dEF1 on Vascular Lesion Formation
(A–G) Real-time PCR analysis of the expres-
sion of dEF1, SIP1, and SMC markers in the
aortas of wild-type, dEF1+/2, and dEF12/2 em-
bryos. Aortas were collected from embryos of
each genotype (n = 3, 4, and 3, respectively),
after which total RNA was isolated from the
collected samples, and real-time PCR was
carried out. The relative numbers of tran-
scripts were normalized to those of 18S, after
which expression of the transcript for each
genotype was further normalized to that of
the wild-type embryo. Error bars represent
SE in real-time PCR data.
(H) Representative photomicrographs of
transverse sections of femoral arteries har-
vested from wild-type and dEF1+/2 mice 4
weeks after injury with a catheter guide wire.
The sections were stained with hematoxylin-
eosin.
(I) Neointimal/medial wall area ratios; bars are
means6 SE; n = 4 for each genotype.SMemb was higher in dEF12/2 embryos than in wild-
type or dEF1+/2 embryos (Figure 6G).
It was interesting to us that although aortic SMCs from
dEF12/2 embryos exhibited retarded differentiation on
E18.5, SMC differentiation marker genes were still ex-
pressed in dEF12/2 embryos, albeit at a lower level. In
that regard, SIP1/ZEB-2, a transcription factor closely
related to dEF1, was expressed in the aortas of E18.5
embryos and adult mice, and its expression was higher
in dEF12/2 than in wild-type embryos (Figure 6B), sug-
gesting that SIP1 might have acted to compensate for
the lack of dEF1 function in the knockout mice (see Dis-
cussion).
dEF1+/2mice do not exhibit a clearly abnormal arterial
phenotype, but we hypothesized that injury might elicit
abnormal responses, as has been seen when other
transcription factor genes were targeted (Manabe and
Nagai, 2003). Moreover, previous studies have dem-
onstrated that alteration of the differentiated state of
SMCs plays an important role in vascular lesion forma-
tion and that changes in the course of phenotypic mod-
ulation and redifferentiation of SMCs during lesion for-
mation may affect the outcome after vascular injury
(Owens et al., 2004; Wiegman et al., 2000). With that in
mind, we carried out vascular injury experiments in
dEF1+/2 knockout mice in which the femoral arterieswere injured by using catheter guide wires. In dEF1+/2
mice, neointimal lesions observed 4 weeks after the in-
jury were much more prominent than in wild-type mice
(Figure 6H), leading to significantly (p < 0.001) higher
intimal/medial area ratios in dEF1+/2 mice (Figure 6I).
Moreover, as expected, we found much reduced ex-
pression of SM a-actin and SM-MHC proteins in the le-
sions of dEF1+/2 mice (Figure S4), indicating redifferen-
tiation of SMCs was disrupted in those animals. By
contrast, we did not find clear differences in the num-
bers of CD45+ leukocytes within the lesions.
dEF1 Is Involved in Controlling the Differentiated
State of SMCs during Neointima Formation In Vivo
We further analyzed the role played by dEF1 in vascular
pathology with a rat vascular injury model that enabled
analysis of gene expression and SMC phenotypes. The
left common carotid arteries of rats were subjected to
balloon injury, after which an adenoviral vector encoding
dEF1 (Ad-dEF1) or empty adenovirus was injected into
the lumens of the injured arteries to infect mural cells.
As evident from arteries exposed to empty adenovirus,
expression of endogenous dEF1 protein was barely de-
tectable in neointimal cells except those located adja-
cent to the tunica media (Figures 7Ac). The neointimal
cells in the arteries exposed to empty adenovirus also
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(A) Representative photomicrographs of transverse sections of rat common carotid arteries harvested 2 weeks after balloon injury and injection
of empty adenoviral vector (Aa, Ac, and Ae) or Ad-dEF1 (Ab, Ad, and Af). (Aa and Ab) The sections were stained with hematoxylin-eosin. (Ac and
Ad) Immunohistochemical staining of dEF1 protein (red). (Ae and Af) Immunohistochemical staining of SM a-actin protein (blue). Nuclei were
counterstained with nuclear fast red. Arrows indicate the internal elastic laminae. Scale bars represent 100 mm.
(B) Neointimal/medial wall area ratios; bars are means 6 SE; n = 8 for each group.
(C–J) Real-time PCR analysis of mRNA expression. Solid lines represent mRNA expression in arteries infected with empty adenovirus; dotted
lines, expression in arteries infected with Ad-dEF1; n = 3 in each group. Copy number of each transcript was normalized to that of 18S, after which
the expression was further normalized to that in arteries without balloon injury and adenovirus injection. Graphs indicate relative copy number
and SE; *p < 0.05 (two-way ANOVA).exhibited weaker staining for SM a-actin than was seen
in medial SMCs (Figure 7Ae), indicating that the neointi-
mal cells were phenotypically modulated. Downregula-
tion of dEF1 was also seen at the mRNA level (Figure 7C).
Ad-dEF1 infection markedly attenuated neointima for-
mation (Figure 7Aa versus 7Ab), so that neointimal/me-
dial wall area ratios were significantly (p < 0.001) lowerin arteries infected with Ad-dEF1 than in those infected
with empty adenovirus (Figure 7B). In the Ad-dEF1-in-
fected arteries, dEF1 was detected in both the media
and the neointima, and similar levels of SM a-actin stain-
ing were detected in medial and neointimal cells (Fig-
ure 7A). This suggests that at this point in time, neointi-
mal cells in the Ad-dEF1-treated arteries exhibit a more
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with empty adenovirus.
We then analyzed mRNA expression in the injured ca-
rotid arteries (Figures 7C–7J) and found that in arteries
infected with empty adenovirus, levels of dEF1 tran-
script were clearly diminished by day 2 after injury and
gradually returning to baseline by day 14 (Figure 7C).
This reduction in dEF1 expression was accompanied
by reductions in SM-MHC and SM a-actin expression
(Figures 7G–7I). In the Ad-dEF1-infected arteries, by
contrast, overexpression of dEF1 was observed until
day 7, and the level of suppression of SM-MHC and
SM a-actin was much attenuated (Figures 7G–7I). Ex-
pression of SMemb, which was induced by injury, was
moderately, but significantly, decreased in the arteries
infected with Ad-dEF1 (Figure 7J). Thus, judging from
the observed expression of SMC phenotype marker
genes, SMCs in Ad-dEF1-infected arteries are in
a more differentiated state than those in control arteries.
We also analyzed expression of other transcription fac-
tors. Interestingly, overexpression of dEF1 resulted in
a reduction in SIP1 expression (Figure 7D), whereas ex-
pression levels of the dEF1 partners, SRF and Smad3,
were not significantly affected by Ad-dEF1 infection (Fig-
ures 7E and 7F).
Discussion
One of the major findings of the present study is that
dEF1 promotes the expression of SMC differentiation
marker genes. dEF1 expression was upregulated during
SMC differentiation of A404 cells (Figure 1C) and in
mouse aorta (Figure 1D). dEF1 transactivated promoters
of the SMC differentiation marker genes (Figure 2A) and
upregulated expression of endogenous SM-MHC and
SM a-actin in cultured SMCs (Figures 2B–2E). Moreover,
knockdown of dEF1 resulted in inhibition of SM a-actin
and SM-MHC induction during SMC differentiation of
A404 cells (Figures 2H and 2I). Taken together, these
findings demonstrate that dEF1 expression is regulated
during vascular development and that, once expressed,
dEF1 controls expression of various SMC differentiation
marker genes and is thus actively involved in SMC differ-
entiation. The role of dEF1 in the control of SMC differen-
tiation was indicated further by the observations that
differentiation of aortic SMCs was delayed in dEF1
knockout mice (Figure 6 and Figure S4) and that differ-
entiation is promoted by dEF1 overexpression in cul-
tured SMCs (Figure 2) and in injured arteries (Figure 7).
Another major finding of the present study is the in-
volvement of dEF1 in TGF-b-dependent SMC transcrip-
tional programs. TGF-b is thought to be one of the most
important environmental cues controlling SMC differen-
tiation (Owens et al., 2004), but little was known about
how TGF-b affects the molecular machinery of SMC
transcriptional programs. We were able to show in the
present study (1) that dEF1 expression is regulated by
TGF-b (Figure 5E); (2) that dEF1 physically interacts
with Smad3 to synergistically enhance SM a-actin re-
porter activity (Figures 5A–5D); (3) that dEF1 also physi-
cally interacts with SRF (Figure 4); (4) that TGF-b induces
binding of dEF1, SRF, and Smad3 to the endogenousSM
a-actin promoter region (Figures 5H–5J); and (5) that
knocking down dEF1 reduces TGF-b-induced upregula-tion of endogenous SM a-actin expression in SMCs
(Figure 5G). Collectively, then, our findings suggest
that dEF1 mediates TGF-b signaling by binding to both
SRF and Smad3, which is consistent with earlier obser-
vations showing that CArG elements are indispensable
for TGF-b-dependent transcriptional activation. Al-
though further studies are needed to confirm whether
dEF1 forms multiprotein complexes (enhanceosomes)
by simultaneously binding SRF, Smad3, and other
factors on the SM a-actin promoter, the results of the
present study provide compelling evidence for the in-
volvement of dEF1 in TGF-b-dependent SMC-specific
transcriptional regulation mediated by SRF and Smad.
The finding of an interaction between dEF1 and SRF
provides insight into SMC transcriptional regulatory pro-
grams that need to respond to diverse environmental
cues (Owens et al., 2004). Identification of a number of
the factors that interact with SRF has led to the hypoth-
esis that protein-DNA complexes comprised of multiple
factors control SMC-specific gene regulation (Miano,
2003; Owens et al., 2004). Recently, a coactivator called
myocardin was reported to be specifically expressed in
SMCs and cardiomyocytes and to dramatically activate
SRF-dependent SMC promoters, suggesting it may be
myocardin that determines the SMC-specificity of the
SRF-dependent transcriptional programs. On the other
hand, myocardin, alone, does not appear to be sufficient
to control SMC transcriptional programs in response to
diverse environmental cues (Parmacek, 2004; Pipes
et al., 2005). dEF1 is interesting in this regard, as it is se-
lectively expressed in vascular SMCs, is regulated by
TGF-b, and interacts with both SRF and Smad. dEF1
thus possesses several characteristics necessary to
mediate context-dependent combinatorial regulation
of SMC genes. Future studies will be needed to address
the role of myocardin in dEF1-mediated transcriptional
control.
The attenuated expression of SMC differentiation
marker genes in the aorta of dEF12/2 mice is indicative
of delayed SMC differentiation there. Still, although the
level was reduced, some expression of SMC differentia-
tion marker genes did occur in dEF12/2 mice, and de-
spite the lethality of the genotype, there were no clear
morphological abnormalities within their cardiovascular
systems. One possible reason for the mildness of the
phenotype is that the loss of dEF1 is compensated for
by other factors. Indeed, SIP1/ZEB-2, a closely related
transcription factor, is also expressed in the aorta, and
the level of its expression was higher in dEF12/2 mice
than in wild-type mice (Figure 6B). This is consistent
with earlier studies showing that dEF12/2 mice exhibit
no clear phenotype in the central nervous system, skel-
etal muscle, or heart, where both dEF1 and SIP1 are ex-
pressed (Postigo and Dean, 2000; Takagi et al., 1998).
dEF1 and SIP1 bind to similar sequences, and we found
that SIP1 is also capable of transactivating SMC differ-
entiation marker gene promoters (G.N. and I.M., unpub-
lished data). That said, it was recently shown that dEF1
and SIP1 have distinctly different functions under cer-
tain conditions (Postigo et al., 2003), so further studies
will be required to clarify the functional relationship be-
tween dEF1 and SIP1.
Finally, we found that expression of dEF1 is downre-
gulated in neointimal SMCs (Figure 7A) and in rat carotid
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(Figure 7C) and that expression of SM a-actin, SM1,
and SM2 is also downregulated during the same period
(Figures 7G–7I). In addition, overexpression of dEF1 in
injured arteries significantly reduced neointima forma-
tion (Figure 7B), whereas neointimal areas were signifi-
cantly larger in the injured arteries of dEF1+/2 mice
than in those of wild-type animals (Figure 6I). The pre-
cise mechanism by which dEF1 expression affects neo-
intima formation is not yet clear, but there are several
possibilities. First, activation of differentiation programs
by dEF1 may affect SMC proliferation, as differentiation
and proliferation are inversely correlated in many cell
types. Indeed, proliferating SMCs in vascular diseases
are known to exhibit modulated phenotypes character-
ized by downregulation of the SMC differentiation
marker genes and upregulation of SMemb (Manabe
and Nagai, 2003). Gene expression patterns of dEF1-
treated arteries and dEF1+/2 animals suggest that dEF1
inhibits phenotypic modulation and/or promotes differ-
entiation of SMCs (Figure 7 and Figure S4). It has also
been shown that transcription factors that control differ-
entiation programs directly affect cell-cycle proteins
and vice versa. In that regard, TGF-b is known to control
SMC proliferation in a context-dependent manner, and
Postigo recently showed that dEF1 acts synergistically
with TGF-b to arrest proliferation of Mv1Lu epithelial
cells (Postigo, 2003). Second, in addition to contractile
protein genes, dEF1 may regulate genes involved in
other functions of SMCs. Neointima formation is a com-
plex process, in which SMCs migrate, proliferate, and
produce extracellular matrices and paracrine factors,
thereby mediating tissue remodeling. The clear sup-
pression of neointima formation by adenovirus-medi-
ated dEF1 expression suggests that dEF1 may modulate
various functions of SMCs in that process. In that re-
gard, it was recently reported that dEF1 controls colla-
gen type 1 expression in the A7r5 cultured SMC line
(Ponticos et al., 2004), which is noteworthy because col-
lagen fibers and other extracellular matrix proteins and
matrix proteases are known to affect SMC function
and the pathology of blood vessels. However, we did
not find that Ad-dEF1 infection significantly affected col-
lagen deposition in the injured carotid arteries (G.N. and
I.M., unpublished data). It would be important to identify
additional dEF1 target genes to further clarify its role in
neointima formation.
dEF1 is among only a few transcription factors that
have been shown to affect neointima formation after vas-
cular injury (Perlman et al., 1998). This suggests that
modulation of dEF1 function may represent a strategy
for treating vascular conditions such as the restenosis
that can occur after percutaneous coronary intervention,
as well as unstable plaque. Moreover, definition of the
transcription factor networks of which dEF1 is one com-
ponent could reveal additional potential targets for ther-
apeutic intervention in the treatment of vascular disease.
Experimental Procedures
Plasmids
ZEB-1 constructs were kindly provided by Dr. D.C. Dean, Smad3
and ALK5 constructs were by Dr. K. Miyazono, and SM-MHC and
SM a-actin reporter constructs were by Dr. G.K. Owens.Animal Models
All animal procedures strictly adhered to the guidelines for animal
experiments of the University of Tokyo.
Chromatin Immunoprecipitation
Confluent SMCs were maintained in serum-free medium for 4 days,
after which TGF-b1 (2.5 ng/ml) was added to the medium. After incu-
bating for an additional 12 hr in the presence of TGF-b1, the cells
were fixed and harvested, and the samples were subjected to chro-
matin immunoprecipitation (ChIP) assays (Manabe and Owens,
2001a). An enhanced Supplemental Experimental Procedures sec-
tion is available online.
Supplemental Data
Supplemental data include an enhanced Experimental Procedures
section and supplemental figures and are available at http://www.
developmentalcell.com/cgi/content/full/11/1/93/DC1/.
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